Dimensional reduction based on peak fitting of Raman micro spectroscopy data improves detection of prostate cancer in tissue specimens.


Journal

Journal of biomedical optics
ISSN: 1560-2281
Titre abrégé: J Biomed Opt
Pays: United States
ID NLM: 9605853

Informations de publication

Date de publication:
11 2021
Historique:
received: 30 06 2021
accepted: 04 10 2021
entrez: 7 11 2021
pubmed: 8 11 2021
medline: 18 11 2021
Statut: ppublish

Résumé

Prostate cancer is the most common cancer among men. An accurate diagnosis of its severity at detection plays a major role in improving their survival. Recently, machine learning models using biomarkers identified from Raman micro-spectroscopy discriminated intraductal carcinoma of the prostate (IDC-P) from cancer tissue with a ≥85  %   detection accuracy and differentiated high-grade prostatic intraepithelial neoplasia (HGPIN) from IDC-P with a ≥97.8  %   accuracy. To improve the classification performance of machine learning models identifying different types of prostate cancer tissue using a new dimensional reduction technique. A radial basis function (RBF) kernel support vector machine (SVM) model was trained on Raman spectra of prostate tissue from a 272-patient cohort (Centre hospitalier de l'Université de Montréal, CHUM) and tested on two independent cohorts of 76 patients [University Health Network (UHN)] and 135 patients (Centre hospitalier universitaire de Québec-Université Laval, CHUQc-UL). Two types of engineered features were used. Individual intensity features, i.e., Raman signal intensity measured at particular wavelengths and novel Raman spectra fitted peak features consisting of peak heights and widths. Combining engineered features improved classification performance for the three aforementioned classification tasks. The improvements for IDC-P/cancer classification for the UHN and CHUQc-UL testing sets in accuracy, sensitivity, specificity, and area under the curve (AUC) are (numbers in parenthesis are associated with the CHUQc-UL testing set): +4  %   (+8  %  ), +7  %   (+9  %  ), +2  %   (6%), +9 (+9) with respect to the current best models. Discrimination between HGPIN and IDC-P was also improved in both testing cohorts: +2.2  %   (+1.7  %  ), +4.5  %   (+3.6  %  ), +0  %   (+0  %  ), +2.3 (+0). While no global improvements were obtained for the normal versus cancer classification task [+0  %   (-2  %  ), +0  %   (-3  %  ), +2  %   (-2  %  ), +4 (+3)], the AUC was improved in both testing sets. Combining individual intensity features and novel Raman fitted peak features, improved the classification performance on two independent and multicenter testing sets in comparison to using only individual intensity features.

Identifiants

pubmed: 34743445
pii: JBO-210212R
doi: 10.1117/1.JBO.26.11.116501
pmc: PMC8571651
doi:

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Références

Am J Surg Pathol. 2020 May;44(5):673-680
pubmed: 31876580
J Phys Chem B. 2006 Oct 5;110(39):19625-31
pubmed: 17004830
Analyst. 2019 Nov 4;144(22):6517-6532
pubmed: 31647061
Br J Cancer. 2003 Jul 7;89(1):106-8
pubmed: 12838309
Appl Spectrosc. 2010 Jun;64(6):595-600
pubmed: 20537226
BJU Int. 2010 Aug;106(4):484-8
pubmed: 20201840
Phys Med Biol. 2016 Dec 7;61(23):R370-R400
pubmed: 27804917
J Biomed Opt. 2013 Aug;18(8):87001
pubmed: 23907278
Cancer Metastasis Rev. 2014 Sep;33(2-3):673-93
pubmed: 24510129
Br J Cancer. 2005 Jun 20;92(12):2166-70
pubmed: 15928665
Analyst. 2010 Dec;135(12):3060-9
pubmed: 20949203
Biometrics. 1988 Sep;44(3):837-45
pubmed: 3203132
PLoS Med. 2020 Aug 14;17(8):e1003281
pubmed: 32797086
Eur Urol. 2016 Jul;70(1):106-119
pubmed: 26996659

Auteurs

Arthur Plante (A)

Centre de recherche du Centre hospitalier de l'Université de Montréal, Montreal, Quebec, Canada.
Institut du cancer de Montréal, Montreal, Quebec, Canada.
Polytechnique Montréal, Department of Engineering Physics, Montreal, Quebec, Canada.

Frédérick Dallaire (F)

Centre de recherche du Centre hospitalier de l'Université de Montréal, Montreal, Quebec, Canada.
Institut du cancer de Montréal, Montreal, Quebec, Canada.
Polytechnique Montréal, Department of Engineering Physics, Montreal, Quebec, Canada.

Andrée-Anne Grosset (AA)

Centre de recherche du Centre hospitalier de l'Université de Montréal, Montreal, Quebec, Canada.
Institut du cancer de Montréal, Montreal, Quebec, Canada.
Université de Montréal, Department of Pathology and Cellular Biology, Montreal, Quebec, Canada.

Tien Nguyen (T)

Centre de recherche du Centre hospitalier de l'Université de Montréal, Montreal, Quebec, Canada.
Institut du cancer de Montréal, Montreal, Quebec, Canada.
Polytechnique Montréal, Department of Engineering Physics, Montreal, Quebec, Canada.

Mirela Birlea (M)

Centre de recherche du Centre hospitalier de l'Université de Montréal, Montreal, Quebec, Canada.
Institut du cancer de Montréal, Montreal, Quebec, Canada.

Jahg Wong (J)

Centre de recherche du Centre hospitalier de l'Université de Montréal, Montreal, Quebec, Canada.
Institut du cancer de Montréal, Montreal, Quebec, Canada.

François Daoust (F)

Centre de recherche du Centre hospitalier de l'Université de Montréal, Montreal, Quebec, Canada.
Institut du cancer de Montréal, Montreal, Quebec, Canada.
Polytechnique Montréal, Department of Engineering Physics, Montreal, Quebec, Canada.

Noémi Roy (N)

Centre de recherche du Centre hospitalier de l'Université de Montréal, Montreal, Quebec, Canada.
Institut du cancer de Montréal, Montreal, Quebec, Canada.

André Kougioumoutzakis (A)

Centre de recherche du Centre hospitalier de l'Université de Montréal, Montreal, Quebec, Canada.
Institut du cancer de Montréal, Montreal, Quebec, Canada.

Feryel Azzi (F)

Centre de recherche du Centre hospitalier de l'Université de Montréal, Montreal, Quebec, Canada.
Institut du cancer de Montréal, Montreal, Quebec, Canada.

Kelly Aubertin (K)

Centre de recherche du Centre hospitalier de l'Université de Montréal, Montreal, Quebec, Canada.
Institut du cancer de Montréal, Montreal, Quebec, Canada.

Samuel Kadoury (S)

Centre de recherche du Centre hospitalier de l'Université de Montréal, Montreal, Quebec, Canada.
Institut du cancer de Montréal, Montreal, Quebec, Canada.
Polytechnique Montréal, Department of Computer Engineering and Software Engineering, Montreal, Quebe, Canada.

Mathieu Latour (M)

Université de Montréal, Department of Pathology and Cellular Biology, Montreal, Quebec, Canada.
Centre hospitalier de l'Université de Montréal, Department of Pathology, Montreal, Quebec, Canada.

Roula Albadine (R)

Université de Montréal, Department of Pathology and Cellular Biology, Montreal, Quebec, Canada.
Centre hospitalier de l'Université de Montréal, Department of Pathology, Montreal, Quebec, Canada.

Susan Prendeville (S)

University Health Network, Laboratory Medicine Program, Toronto, Ontario, Canada.

Paul Boutros (P)

Informatics & Biocomputing Program, Ontario Institute for Cancer Research, Toronto, Ontario, Canada.
University of California, Los Angeles, Department of Human Genetics, Los Angeles, California, United States.
University of California, Los Angeles, Department of Urology, Los Angeles, California, United States.

Michael Fraser (M)

Informatics & Biocomputing Program, Ontario Institute for Cancer Research, Toronto, Ontario, Canada.
University Health Network, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.

Rob G Bristow (RG)

University Health Network, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.

Theodorus van der Kwast (T)

University Health Network, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.

Michèle Orain (M)

Centre de recherche du Centre hospitalier universitaire de Québec-Université Laval, Oncology Divisio, Canada.
Université Laval, Centre de recherche sur le cancer, Quebec City, Quebec, Canada.

Hervé Brisson (H)

Centre de recherche du Centre hospitalier universitaire de Québec-Université Laval, Oncology Divisio, Canada.
Université Laval, Centre de recherche sur le cancer, Quebec City, Quebec, Canada.

Nazim Benzerdjeb (N)

Centre de recherche du Centre hospitalier de l'Université de Montréal, Montreal, Quebec, Canada.
Institut du cancer de Montréal, Montreal, Quebec, Canada.
Centre de recherche du Centre hospitalier universitaire de Québec-Université Laval, Oncology Divisio, Canada.

Hélène Hovington (H)

Centre de recherche du Centre hospitalier universitaire de Québec-Université Laval, Oncology Divisio, Canada.
Université Laval, Centre de recherche sur le cancer, Quebec City, Quebec, Canada.

Alain Bergeron (A)

Centre de recherche du Centre hospitalier universitaire de Québec-Université Laval, Oncology Divisio, Canada.
Université Laval, Centre de recherche sur le cancer, Quebec City, Quebec, Canada.
Université Laval, Department of Surgery, Quebec City, Quebec, Canada.

Yves Fradet (Y)

Centre de recherche du Centre hospitalier universitaire de Québec-Université Laval, Oncology Divisio, Canada.
Université Laval, Centre de recherche sur le cancer, Quebec City, Quebec, Canada.
Université Laval, Department of Surgery, Quebec City, Quebec, Canada.

Bernard Têtu (B)

Centre de recherche du Centre hospitalier universitaire de Québec-Université Laval, Oncology Divisio, Canada.
Université Laval, Centre de recherche sur le cancer, Quebec City, Quebec, Canada.

Fred Saad (F)

Centre de recherche du Centre hospitalier de l'Université de Montréal, Montreal, Quebec, Canada.
Institut du cancer de Montréal, Montreal, Quebec, Canada.

Dominique Trudel (D)

Centre de recherche du Centre hospitalier de l'Université de Montréal, Montreal, Quebec, Canada.
Institut du cancer de Montréal, Montreal, Quebec, Canada.
Polytechnique Montréal, Department of Engineering Physics, Montreal, Quebec, Canada.

Frédéric Leblond (F)

Centre de recherche du Centre hospitalier de l'Université de Montréal, Montreal, Quebec, Canada.
Institut du cancer de Montréal, Montreal, Quebec, Canada.
Polytechnique Montréal, Department of Engineering Physics, Montreal, Quebec, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH